UY31210A1 - Formulaciones de anticuerpos - Google Patents
Formulaciones de anticuerposInfo
- Publication number
- UY31210A1 UY31210A1 UY31210A UY31210A UY31210A1 UY 31210 A1 UY31210 A1 UY 31210A1 UY 31210 A UY31210 A UY 31210A UY 31210 A UY31210 A UY 31210A UY 31210 A1 UY31210 A1 UY 31210A1
- Authority
- UY
- Uruguay
- Prior art keywords
- formulations
- temperature
- standard formulation
- antibodies
- antibody formulations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
Abstract
Esta invención se refiere a formulaciones de anticuerpo estables a la temperatura y la cizalladura, que son más estables comparardas con una formulación estándar (tal como citrato 30mM, NaCI 100 mM, pH 6,5). Las formulaciones de anticuerpo estables a la temperatura y la cizalladura de la presente invención mostraron menor precipitación cuando se sometían a condiciones de tensión, mientras que la formulación estándar se había agregado. Este resultado era impredecible porque termodinámicamente las dos formulaciones son similares, como se ve por sus perfiles de DSC (calorimetría diferencial de barrido).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94822007P | 2007-07-06 | 2007-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY31210A1 true UY31210A1 (es) | 2009-01-30 |
Family
ID=40228991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY31210A UY31210A1 (es) | 2007-07-06 | 2008-07-04 | Formulaciones de anticuerpos |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US20110020328A1 (es) |
| EP (2) | EP2170388B1 (es) |
| JP (1) | JP5529017B2 (es) |
| KR (2) | KR20100038092A (es) |
| CN (1) | CN101820912B (es) |
| AR (2) | AR067455A1 (es) |
| AU (1) | AU2008275278B2 (es) |
| BR (2) | BR122020026978B1 (es) |
| CA (1) | CA2692681C (es) |
| CL (1) | CL2008001984A1 (es) |
| CO (1) | CO6270340A2 (es) |
| CR (1) | CR11249A (es) |
| CY (2) | CY1118419T1 (es) |
| DK (2) | DK2889310T3 (es) |
| DO (1) | DOP2010000001A (es) |
| EA (1) | EA017994B1 (es) |
| ES (2) | ES2610821T3 (es) |
| FR (1) | FR21C1040I1 (es) |
| HK (2) | HK1207652A1 (es) |
| HR (2) | HRP20170033T1 (es) |
| HU (3) | HUE038501T2 (es) |
| IL (1) | IL202950A (es) |
| JO (1) | JO3219B1 (es) |
| LT (3) | LT2889310T (es) |
| MA (1) | MA31471B1 (es) |
| MX (1) | MX2010000017A (es) |
| NO (2) | NO2889310T3 (es) |
| NZ (1) | NZ582250A (es) |
| PE (1) | PE20090738A1 (es) |
| PL (2) | PL2170388T3 (es) |
| PT (2) | PT2170388T (es) |
| SI (2) | SI2170388T1 (es) |
| TR (1) | TR201802928T4 (es) |
| TW (2) | TWI612060B (es) |
| UA (1) | UA107557C2 (es) |
| UY (1) | UY31210A1 (es) |
| WO (1) | WO2009009407A1 (es) |
| ZA (1) | ZA200909107B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| EP2173163A4 (en) * | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | ANTIBODY FORMULATIONS |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| JP2013520476A (ja) | 2010-02-26 | 2013-06-06 | ノヴォ ノルディスク アー／エス | 安定な抗体含有組成物 |
| MX2012010198A (es) | 2010-03-01 | 2012-10-03 | Bayer Healthcare Llc | Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi). |
| WO2011147921A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
| JP2014510152A (ja) * | 2011-04-07 | 2014-04-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 粘度が低減された処方物 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| KR20230021758A (ko) * | 2011-05-02 | 2023-02-14 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-α4β7 항체에 대한 제형 |
| UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| EP2968083B1 (en) * | 2013-03-12 | 2021-09-22 | Primal Therapies, Inc. | Dental composition comprising chelator and base |
| EP2805730A1 (en) * | 2013-05-21 | 2014-11-26 | Bergen Teknologioverforing AS | Nitric oxide donor for the treatment of chronic fatigue syndrome |
| WO2015162504A1 (en) | 2014-04-23 | 2015-10-29 | Novartis Ag | Novel dosing and uses of ofatumumab |
| WO2016189491A1 (en) * | 2015-05-28 | 2016-12-01 | Glaxosmithkline Intellectual Property Development Limited | Novel formulation |
| CA3013336A1 (en) * | 2016-02-03 | 2017-08-10 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| IL302488A (en) | 2016-08-15 | 2023-06-01 | Novartis Ag | Dosing regimens and methods for the treatment of multiple sclerosis using opatumumab |
| WO2018179138A1 (ja) * | 2017-03-29 | 2018-10-04 | 持田製薬株式会社 | 抗体含有液体製剤 |
| US10799597B2 (en) | 2017-04-03 | 2020-10-13 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CA3033195A1 (en) * | 2018-02-09 | 2019-08-09 | Ecolab Usa Inc. | Flowability testing systems and methods |
| EP3864053B1 (en) | 2019-09-11 | 2023-07-05 | Novartis AG | Treatment of rms by switching therapy |
| KR20220062027A (ko) | 2019-09-11 | 2022-05-13 | 노파르티스 아게 | 오파투무맙-치료된 환자에서의 다발성 경화증 이외의 병태의 관리 |
| CN112675126A (zh) * | 2019-10-18 | 2021-04-20 | 百奥泰生物制药股份有限公司 | 抗cd20抗体制剂及其应用 |
| BR112022019038A2 (pt) | 2020-04-09 | 2022-11-01 | Novartis Ag | Ofatumumab para tratamento de em enquanto mantém a igg sérica |
| JP7057954B2 (ja) * | 2020-09-03 | 2022-04-21 | 国立大学法人大阪大学 | 改善された保存安定性を有するタンパク質含有液体製剤 |
| CA3216479A1 (en) | 2021-04-14 | 2022-10-20 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
| CA3229704A1 (en) | 2021-08-16 | 2023-02-23 | Novartis Ag | Ofatumumab for treating pediatric ms |
| WO2023204554A1 (ko) * | 2022-04-20 | 2023-10-26 | 주식회사 알토스바이오로직스 | 오크렐리주맙을 포함하는 약학적 조성물과 그의 용도 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4816401A (en) * | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| JP3919235B2 (ja) * | 1997-06-13 | 2007-05-23 | ジェネンテク，インコーポレイテッド | 抗体製剤 |
| IL149008A0 (en) * | 1999-10-04 | 2002-11-10 | Chiron Corp | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP2295468B1 (en) | 2002-02-14 | 2015-07-08 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
| ES2618832T3 (es) * | 2002-02-27 | 2017-06-22 | Immunex Corporation | Composición TNFR-FC estabilizada que comprende arginina |
| CA2490423A1 (en) * | 2002-06-21 | 2003-12-31 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
| CA2502552C (en) | 2002-10-17 | 2019-02-12 | Genmab A/S | Human monoclonal antibodies against cd20 |
| ES2373947T3 (es) * | 2002-12-16 | 2012-02-10 | Genmab A/S | Anticuerpos monoclonales humanos contra interleucina 8 (il-8). |
| US8084582B2 (en) * | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| AR062247A1 (es) * | 2005-03-08 | 2008-10-29 | Pharmacia & Upjohn Co Llc | Composiciones de anticuerpos anti-ctla-4 |
| EP1942939B2 (en) * | 2005-09-30 | 2021-07-07 | Medimmune Limited | Interleukin-13 antibody composition |
| EP2173163A4 (en) * | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | ANTIBODY FORMULATIONS |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу |
-
2008
- 2008-03-07 UA UAA201001165A patent/UA107557C2/ru unknown
- 2008-07-03 ES ES08781323.4T patent/ES2610821T3/es active Active
- 2008-07-03 NO NO15155712A patent/NO2889310T3/no unknown
- 2008-07-03 CN CN200880105866.1A patent/CN101820912B/zh active Active
- 2008-07-03 PT PT87813234T patent/PT2170388T/pt unknown
- 2008-07-03 EP EP08781323.4A patent/EP2170388B1/en active Active
- 2008-07-03 EA EA201070105A patent/EA017994B1/ru not_active IP Right Cessation
- 2008-07-03 HU HUE15155712A patent/HUE038501T2/hu unknown
- 2008-07-03 SI SI200831738A patent/SI2170388T1/sl unknown
- 2008-07-03 US US12/667,890 patent/US20110020328A1/en not_active Abandoned
- 2008-07-03 HU HUE08781323A patent/HUE031288T2/hu unknown
- 2008-07-03 PL PL08781323T patent/PL2170388T3/pl unknown
- 2008-07-03 CA CA2692681A patent/CA2692681C/en active Active
- 2008-07-03 MX MX2010000017A patent/MX2010000017A/es active IP Right Grant
- 2008-07-03 TR TR2018/02928T patent/TR201802928T4/tr unknown
- 2008-07-03 DK DK15155712.1T patent/DK2889310T3/en active
- 2008-07-03 WO PCT/US2008/069125 patent/WO2009009407A1/en active Application Filing
- 2008-07-03 KR KR1020107000148A patent/KR20100038092A/ko not_active Application Discontinuation
- 2008-07-03 DK DK08781323.4T patent/DK2170388T3/en active
- 2008-07-03 KR KR1020157019741A patent/KR101670454B1/ko active IP Right Grant
- 2008-07-03 LT LTEP15155712.1T patent/LT2889310T/lt unknown
- 2008-07-03 PT PT151557121T patent/PT2889310T/pt unknown
- 2008-07-03 BR BR122020026978-2A patent/BR122020026978B1/pt active IP Right Grant
- 2008-07-03 EP EP15155712.1A patent/EP2889310B1/en active Active
- 2008-07-03 BR BRPI0814003-0A patent/BRPI0814003B1/pt active IP Right Grant
- 2008-07-03 NZ NZ582250A patent/NZ582250A/en unknown
- 2008-07-03 AU AU2008275278A patent/AU2008275278B2/en active Active
- 2008-07-03 LT LTEP08781323.4T patent/LT2170388T/lt unknown
- 2008-07-03 JP JP2010516158A patent/JP5529017B2/ja active Active
- 2008-07-03 PL PL15155712T patent/PL2889310T3/pl unknown
- 2008-07-03 JO JOP/2008/0312A patent/JO3219B1/ar active
- 2008-07-03 ES ES15155712.1T patent/ES2663504T3/es active Active
- 2008-07-03 SI SI200831928T patent/SI2889310T1/en unknown
- 2008-07-04 UY UY31210A patent/UY31210A1/es not_active Application Discontinuation
- 2008-07-04 TW TW104128324A patent/TWI612060B/zh active
- 2008-07-04 PE PE2008001136A patent/PE20090738A1/es active IP Right Grant
- 2008-07-04 AR ARP080102910A patent/AR067455A1/es unknown
- 2008-07-04 TW TW097125246A patent/TWI515204B/zh active
- 2008-07-04 CL CL2008001984A patent/CL2008001984A1/es unknown
-
2009
- 2009-12-21 ZA ZA2009/09107A patent/ZA200909107B/en unknown
- 2009-12-24 IL IL202950A patent/IL202950A/en active IP Right Grant
- 2009-12-30 CO CO09149371A patent/CO6270340A2/es active IP Right Grant
- 2009-12-30 MA MA32460A patent/MA31471B1/fr unknown
-
2010
- 2010-01-05 DO DO2010000001A patent/DOP2010000001A/es unknown
- 2010-02-02 CR CR11249A patent/CR11249A/es unknown
- 2010-09-02 HK HK15108178.0A patent/HK1207652A1/xx unknown
- 2010-09-02 HK HK10108319.5A patent/HK1141979A1/zh unknown
-
2015
- 2015-02-19 US US14/625,881 patent/US20150158951A1/en not_active Abandoned
-
2017
- 2017-01-10 HR HRP20170033TT patent/HRP20170033T1/hr unknown
- 2017-01-12 CY CY20171100043T patent/CY1118419T1/el unknown
- 2017-08-29 AR ARP170102392A patent/AR109461A2/es not_active Application Discontinuation
-
2018
- 2018-03-14 HR HRP20180440TT patent/HRP20180440T1/hr unknown
- 2018-03-20 CY CY20181100325T patent/CY1120047T1/el unknown
-
2021
- 2021-09-13 NO NO2021036C patent/NO2021036I1/no unknown
- 2021-09-14 FR FR21C1040C patent/FR21C1040I1/fr active Active
- 2021-09-15 HU HUS2100038C patent/HUS2100038I1/hu unknown
- 2021-09-15 LT LTPA2021520C patent/LTPA2021520I1/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY31210A1 (es) | Formulaciones de anticuerpos | |
| CY1112781T1 (el) | 2'-φθορο-2'-δεοξυτετραϋδροουριδινες ως αναστολεις αποαμινασης κυτιδινης | |
| CY1115893T1 (el) | Anti-μολυσματικες πυριμιδινες και χρησεις αυτων | |
| CY1112653T1 (el) | Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης | |
| DK2074143T3 (da) | Ændrede antistoffer | |
| HRP20070078A2 (en) | Nucleoside phosphonate conjugates as anti hiv agents | |
| GT200600084A (es) | Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen | |
| UY32557A (es) | Composición endulzante que comprende una forma de rebaudiosida a de alta solubilidad y método para su producción | |
| HRP20070043A2 (en) | Antiviral compounds | |
| TR201907244T4 (tr) | Anti̇parazi̇ti̇k di̇hi̇droazol bi̇leşi̇mleri̇ | |
| NI201200023A (es) | Derivados de 5-fluoropirimidinona | |
| CO6741214A2 (es) | Composiciones pesticidas y procesos relacionados | |
| ATE528989T1 (de) | Kristalline feste rasagilin-base | |
| BRPI0715579A2 (pt) | "composto, composição farmacêutica e uso de um composto" | |
| ME01518B (me) | Novi pirazol-4-n-alkoksikarboksamidi kao mikrobiocidi | |
| GT200600346A (es) | Nueva fórmula cristalina v de la agomelatina, un proceso para su preparación y composiciones farmacéuticas que la contienen | |
| RS54217B1 (en) | SOME TRIAZOLOPIRAZINS, THEIR COMPOSITIONS AND THE METHODS OF USING THEM | |
| CY1116048T1 (el) | Μια κρυσταλλικη μορφη τιγεκυκλινης και διαδικασιες για την παρασκευη της | |
| GT200500292A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica | |
| BRPI1015043A2 (pt) | derivados de diazahomoadamantano e métodos de uso dos mesmos | |
| ATE509931T1 (de) | Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür | |
| EA201071183A1 (ru) | Безводная кристаллическая форма малеата орвепитанта | |
| BRPI0603784A (pt) | lubrificante pessoal vaporizável | |
| CY1116319T1 (el) | Συνθεσεις που περιλαμβανουν core-1 θετικο μικροοργανισμο και χρηση αυτων για την αντιμετωπιση ή προφυλαξη απο ογκους | |
| ATE552832T1 (de) | Antidepressivum-propharmaka |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RDES | Application refused |
Effective date: 20200710 |